Group 1 - The core viewpoint of the news is that the Hong Kong pharmaceutical sector is experiencing a rebound, particularly in innovative drug stocks, with the Hong Kong Stock Connect Innovative Drug ETF (520880) rising over 3% after a period of decline [1][4] - The Hong Kong Stock Connect Innovative Drug ETF (520880) recorded five consecutive days of decline, reaching a historical low, but saw a capital inflow of over 135 million yuan during this period [1][2] - The healthcare sector in Hong Kong is showing signs of recovery, with major stocks like WuXi Biologics and BeiGene contributing to the rise of the Hong Kong Stock Connect Healthcare ETF [4][6] Group 2 - The total amount of business development (BD) for innovative drugs in China exceeded 50 billion USD in the first two months of 2026, with upfront payments surpassing 3 billion USD, indicating a strong growth trajectory [3] - Chinese pharmaceutical companies are entering a commercialization phase, with companies like Rongchang Bio turning a profit of 709 million yuan in 2025, and BeiGene achieving its first non-GAAP net profit [3] - China National Pharmaceutical Group's stock surged over 5% following the announcement of an exclusive licensing agreement with Sanofi, which includes an upfront payment of 135 million USD and potential milestone payments of up to 1.395 billion USD [1][3]

3月5日早盘，港股医药终于反弹！创新药龙头普涨，100%创新药研发标的——港股通创新药ETF （520880）高开高走，现涨超3%。昨日，520880录得五连跌，场内价格创下历史新低，不过资金逆行 增仓，连续5日低吸合计逾1.35亿元。 投创新药，认准港股通创新药ETF（520880）及其场外联接基金（025221），100%布局创新药研发类 公司，前十大权重股占比超七成，龙头属性突出。 注： ETF 基金不收取销售服务费。投资者在申购或赎回基金份额时，申购赎回代理券商可按照不超过 0.5% 的标准收取佣金，其中包含证券交易所、登记机构等收取的相关费用。基金费率详见各基金法律 文件。 | 分时 多日 1分 · | | | | | F9 盘前盘后 露加 九粒 酒线 工具 (8 (7) > | | | | | | 港股通创新药ETF ① | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 0.468 | | | 520880[用胶通创新的ETF] 10:06 价 0.468 新跌 ...

2月27日，A股医疗板块全天飘红，全市场规模最大医疗ETF（512170）盘中上探1.14%，成功收复年 线，成交3.84亿元。场内持续溢价交易，显示买盘态度积极，此前3日512170累获逾1.9亿元净申购。 | 分时 多日 1分 5分 * | | | | F9 盘前盘后 徽加 九特 画线 工具 @ (2 )> | | | | | 顾疗ETF O | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 512170医疗ETF] 15:00 价 0.355 通联 0.003(0.85%) 均价 0.354 1 512170(医疗器价交易 | | | | 0.354 +0.002 +0.57% | | 512170 | | | | 0.355 | | A NAT THE | | A CAL WHEY YOUNG WALL OLT OF O | | | SSE CNY 15:00:16 图布 查看L2全覆 | | 通政人员干 | | | | | | | | | | 净值走势 | | 华宝中让医疗L ...

2月26日午后，港股医药股加速走低，创新药产业链跌幅靠前，港股通创新药ETF（520880） 、港股通 医疗ETF华宝（159137）双双跌逾2%，场内溢价同步走高，显示"抄底"资金有所行动。 个股方面，权重龙头百济神州跌逾6%居首，据悉，该公司将于今日披露2025年财报。作为创新药领域 龙头企业，百济神州为港股通创新药ETF（520880） 、港股通医疗ETF华宝（159137）持仓股，权重占 比分别为11.27%、2.13%。 开源证券指出，中国创新药正经历从"规模积累"走向"价值释放"的国际化跨越，并持续迎来从"管线预 期"转向"业绩兑现"的商业化收获期。创新药板块已回调两个季度，长期看，较多优质标的估值性价比 明显，当前位置建议加大关注。* 低位埋伏港股医药机遇，借道ETF效率更高，高弹性，T+0！ 投创新药，认准港股通创新药ETF（520880）及其场外联接基金（025221），100%布局创新药研发类 公司，前十大权重股占比超七成，龙头属性突出。 投医疗，选港股通医疗ETF华宝（159137），锚定医疗创新，囊括脑机接口、AI医疗、互联网药店等热 点概念，同时覆盖创新药全产业链龙头。 数据来源：中 ...

Group 1 - The Hong Kong stock market for innovative drugs experienced a decline, with the Hong Kong Stock Connect Innovative Drug ETF (520880) dropping by 2%, and major stocks like CSPC Pharmaceutical, China Biologic Products, and Hansoh Pharmaceutical falling over 2% [1] - The market is expected to see a traditional surge during the Chinese New Year holiday, with an average increase of 2% since 2021 [1] - CICC highlights four key sectors in the A-share market: dividends, internet, innovative drugs, and new consumption, which are considered to have long-term investment value [1] Group 2 - Chinese innovative drugs continue to gain traction internationally, with significant business development (BD) deals, including a partnership between Innovent Biologics and Eli Lilly worth up to $8.85 billion [2] - In January, CSPC Pharmaceutical announced a partnership with AstraZeneca valued at up to $18.5 billion, showcasing the global competitiveness of Chinese innovative drugs [2] Group 3 - The Chinese innovative drug sector is entering a commercialization phase, with over 70% of innovative drug companies reporting revenue growth, and companies like BeiGene achieving revenues exceeding 36 billion yuan [3] - Leading companies are starting to achieve profitability, with firms like Innovent Biologics and Rongchang Biologics reaching annual breakeven, and Elysium achieving over 2 billion yuan in net profit [3] - Open Source Securities expresses optimism about the innovative drug sector and its supply chain, as well as emerging industries like AI and biomanufacturing [3] Group 4 - The Hong Kong pharmaceutical sector has adjusted for nearly two quarters, presenting an attractive investment opportunity, particularly through ETFs for efficient capital allocation [3] - The Hong Kong Stock Connect Innovative Drug ETF (520880) focuses on innovative drug R&D companies, with the top ten holdings accounting for over 73% of the portfolio [3]

2月11日，港股医药有所分化。创新药大面积回调，创新药纯度100%的港股通创新药ETF（520880）微 跌0.19%止步三连阳。医疗主题板块继续上行，港股通医疗ETF华宝（159137）走出四连涨，站上20日 均线。 | 分时 多日 1分 5分 15分 30分 · 给会屏 F9 后复农 超级盘加 面试 工具 @ (1) > | | 港般通医疗ETF华宝 | | 159137 | | --- | --- | --- | --- | --- | | 159137.SZ[桃投通四疗ETF华宜] 2026/02/11 歌 1.024 幅0.49%(0.005) 开 1.025 高 1.030 低 1.019 均回 | | | | | | MAS 1.0021 MA10 0.998 MA20 1.022 2026/01/12-2026/02/11(23日)▼ | | 0 | | +0.005 +0.499 | | | 1,160 | SZSE CNY 15:00:00 闭槽 | | T+0 / 0 | | 4-1,152 | | 净值走势 | | 华宝中证港股通医疗主题ETF | | | | DEF | -51.86 ...

Market Overview - A-shares experienced narrow fluctuations, with the Sci-Tech Innovation Board showing strong performance, particularly in AI applications and computing chips [1] - The Hong Kong stock market saw a significant rebound in the pharmaceutical sector, with the Hong Kong Innovation Drug ETF (520880) reaching a peak increase of 3.86% and closing up 2.9% [3][5] ETF Performance - The Hong Kong Innovation Drug ETF (520880) recorded a trading volume of 5.9 billion, while the Hong Kong Medical ETF (159137) rose by 2.1%, marking its sixth consecutive day of gains [2][3] - The Sci-Tech Artificial Intelligence ETF (589520) increased by 1.81%, with a peak rise of over 2.4% during the trading session [8] Industry Insights - The Chinese innovative drug sector is experiencing a dual breakthrough in internationalization and commercialization, with over 70% of innovative drug companies reporting positive revenue growth [6][7] - Significant collaborations in the innovative drug space include a strategic partnership between Innovent Biologics and Eli Lilly, valued at up to $8.85 billion, and a $18.5 billion collaboration between CSPC Pharmaceutical and AstraZeneca [6] AI and Technology Developments - ByteDance's recent launches, including the Seedance 2.0 video generation model and Seedream 5.0 image generation model, have generated significant interest in the AI sector [11] - The Sci-Tech Artificial Intelligence ETF (589520) has a substantial exposure to ByteDance, with a weight of 29.42% in its index [11][13] Semiconductor and Chip Industry - The semiconductor equipment industry is experiencing an upward trend, with projected sales growth of 26% in 2026, reaching $791.7 billion [17] - The Sci-Tech Chip ETF (589190) is positioned to benefit from the ongoing "super cycle" in the semiconductor industry, with a focus on domestic production and expansion [15][17] Investment Strategy - Analysts suggest that the current market conditions present a favorable opportunity for investment in innovative drugs and AI sectors, with a recommendation to focus on ETFs that track these industries [7][19] - The Sci-Tech Chip ETF has shown a strong annualized return of 17.93%, outperforming other semiconductor indices [19][20]

Group 1 - The core viewpoint is that the Hong Kong pharmaceutical sector is experiencing a strong resurgence, driven by the innovative drug industry chain, particularly led by Innovent Biologics [1][8] - The Hong Kong Stock Connect Innovative Drug ETF (520880) reached a peak of 3.86% and closed up 2.9%, recovering the 20-day moving average with a trading volume of 590 million yuan [1][8] - The Hong Kong Stock Connect Medical ETF (159137), which has a high CXO content, rose by 2.1%, marking its sixth consecutive day of gains [1][8] Group 2 - The Chinese innovative drug sector is witnessing a robust international expansion, with significant business development (BD) transactions occurring [4][10] - Notable collaborations include Innovent Biologics' announcement of a global strategic partnership with Eli Lilly worth up to $8.85 billion, including an upfront payment of $350 million [4][10] - In January, CSPC Pharmaceutical Group entered a platform-level collaboration with AstraZeneca valued at up to $18.5 billion, while Rongchang Biologics secured a $5.6 billion licensing deal with AbbVie, showcasing the global competitiveness of Chinese innovative drugs [4][10] Group 3 - The Chinese innovative drug industry is entering a commercialization phase, with over 70% of innovative drug companies achieving positive revenue growth by 2025 [5][11] - BeiGene reported revenue exceeding 36 billion yuan, demonstrating strong commercialization capabilities [5][11] - Leading companies like Innovent Biologics and Rongchang Biologics have achieved annual breakeven, while Elysium has reported over 2 billion yuan in net profit attributable to shareholders, indicating a transition from R&D investment to performance realization [5][11] Group 4 - Open Source Securities expresses a positive outlook on the innovative drug sector and its supply chain (CXO + research services), as well as emerging national strategic industries such as AI, brain-computer interfaces, and biomanufacturing [5][11] - The Hong Kong pharmaceutical sector has adjusted for nearly two quarters, presenting an attractive investment opportunity [5][11] - Investors are encouraged to consider the Hong Kong Stock Connect Innovative Drug ETF (520880) and its associated funds, which focus on innovative drug research companies, with the top ten weighted stocks accounting for over 73% [5][11]

Core Viewpoint - The Hong Kong pharmaceutical sector is experiencing significant activity, driven by major licensing deals and a shift towards commercialization of innovative drugs, indicating a potential investment opportunity in this space [1][3]. Group 1: Market Activity - Hong Kong pharmaceutical stocks are active, with notable increases in companies like Innovent Biologics, which saw a rise of 7.42% followed by an additional 5% increase, alongside significant gains in other firms such as Zai Lab and CSPC Pharmaceutical [1]. - The Hong Kong Stock Connect Innovative Drug ETF (520880) has shown strong performance, rising over 2% and recovering above the 20-day moving average [1]. Group 2: Licensing Deals - The total transaction scale for China's innovative drug licensing-out reached a record $135.7 billion in 2025, with significant collaborations in January 2026, including deals between CSPC and AstraZeneca ($18.5 billion) and Rongchang and AbbVie ($5.6 billion), highlighting the global value of domestic innovative drug pipelines [1][2]. Group 3: Industry Trends - The innovative drug sector in China is transitioning from "scale accumulation" to "value release," with a focus on commercializing drug pipelines, suggesting a period of performance realization for the industry [3]. - The Hong Kong medical sector is showing strength, with the innovative drug industry chain leading the gains, as evidenced by the performance of the Hong Kong Stock Connect Medical ETF [3]. Group 4: Investment Recommendations - Analysts recommend increasing attention to high-growth and improving expectation sectors within the pharmaceutical industry, as the impact of medical insurance cost control has been fully reflected in market expectations [3][4].

开源证券指出，中国创新药正经历从"规模积累"走向"价值释放"的国际化跨越，并持续迎来从"管线预 期"转向"业绩兑现"的商业化收获期。创新药板块已回调近两个季度，长期看，较多优质标的估值性价 比明显，当前位置建议加大关注。 湘财证券研报表示，站在当前时点来看，医药行业受医保控费影响的预期已充分反映，多层次的支付体 系正在建立，医疗需求的刚性将共同推动行业企稳回升，建议关注高成长及预期改善两大方向。 低位埋伏港股医药机遇，借道ETF效率更高，高弹性，T+0。港股通创新药ETF（520880）及其场外联 接基金（025221），100%布局创新药研发类公司，前十大权重股占比超73%，龙头属性突出。港股通 医疗ETF华宝（159137），锚定医疗创新，囊括脑机接口、AI医疗、互联网药店等热点概念，同时覆盖 创新药全产业链龙头。 2月份以来，港股医药、医疗以一波强势连阳行情，持续修复失地。热门ETF方面，2月10日，港股通创 新药ETF（520880）、港股通医疗ETF（159137）早盘悉数涨逾2%，其中，港股通创新药ETF （520880）涨幅更是逼近3%。值得一提的是，自2月份以来的7个交易日，上述2只ETF双双 ...